ENTITY
Glenmark Pharmaceuticals

Glenmark Pharmaceuticals (GNP IN)

183
Analysis
Health Care • India
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company that develops, manufactures, and markets branded and generic formulations, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company focuses on therapeutic areas including respiratory, dermatology, and oncology, with products such as Ryaltris, Winlevi, and Candid. It was founded in 1977 and is headquartered in Mumbai, India.
more
•18 Feb 2019 00:00

Glenmark - Earnings Flash - Q3 FY 2018-19 Results - Lucror Analytics

Glenmark’s Q3/18-19 results very much surprised on the upside, with strong revenue and earnings growth after a few weak quarters. This was thanks...

Logo
135 Views
Share
•04 Feb 2019 00:00

Asia HY Monthly - Agency Ratings For Asian Issuers - Lucror Analytics

In this month’s “In-Focus” section, we look at agency ratings for Asian issuers. The Asia Monthly focuses on providing updates on recent events,...

Logo
288 Views
Share
•25 Jan 2019 00:00

Asia HY Trade Recommendations - January 2019 - Lucror Analytics

The Asia HY Trade Recommendations report for January includes a summary of our recommendations, as well as our high-conviction ideas. We also...

Logo
221 Views
Share
bearish•Aurobindo Pharma
•01 Jan 2019 22:29

India Generic Drugs: Antitrust Suit Could Cost Billions

This Insight builds on our previous Insight, India Generic Drugs: US Antitrust Inquiry Widens by discussing estimated potential liabilities and...

Share
•02 Nov 2018 00:00

Asia HY Monthly - Corporate Governance In Chinese Companies - Lucror Analytics

In this month’s “In-Focus” section, we discuss Corporate Governance in Chinese Companies. Specifically, we highlight: [1] the nascent development...

Logo
232 Views
Share
x